Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Relay Therapeutics (RLAY) EPS (Weighted Average and Diluted) (2021 - 2025)

Relay Therapeutics (RLAY) has disclosed EPS (Weighted Average and Diluted) for 5 consecutive years, with -$0.31 as the latest value for Q4 2025.

  • On a quarterly basis, EPS (Weighted Average and Diluted) rose 26.19% to -$0.31 in Q4 2025 year-over-year; TTM through Dec 2025 was -$1.61, a 31.78% increase, with the full-year FY2025 number at -$1.61, up 31.78% from a year prior.
  • EPS (Weighted Average and Diluted) was -$0.31 for Q4 2025 at Relay Therapeutics, up from -$0.43 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of -$0.31 in Q4 2025 to a low of -$0.81 in Q2 2023.
  • A 5-year average of -$0.59 and a median of -$0.62 in 2021 define the central range for EPS (Weighted Average and Diluted).
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 36.84% in 2023, then surged 41.43% in 2025.
  • Relay Therapeutics' EPS (Weighted Average and Diluted) stood at -$0.62 in 2021, then increased by 11.29% to -$0.55 in 2022, then decreased by 20.0% to -$0.66 in 2023, then skyrocketed by 36.36% to -$0.42 in 2024, then increased by 26.19% to -$0.31 in 2025.
  • Per Business Quant, the three most recent readings for RLAY's EPS (Weighted Average and Diluted) are -$0.31 (Q4 2025), -$0.43 (Q3 2025), and -$0.41 (Q2 2025).